Bictegravir vs Cabotegravir (Apretude)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir · Biktarvy
Marketed by Gilead Sciences
NCT02607956 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.
Next expected readout: December 2026 · NCT06830668 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)
Result source: NCT03110380
Cabotegravir (Apretude)
Marketed by GlaxoSmithKline
NCT02720094 · Phase 2/3 · completed
The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).
Next expected readout: August 2028 · NCT06474364 (registry estimate)
Reported efficacy
Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.); Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events (Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).): Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 (met)
Result source: NCT02720094
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir | Cabotegravir (Apretude) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 92.4% vs 93%vs ABC/DTG/3TCNCT026079305 other results
| —Trial running · NCT06133686 |
| HIV-1 RNA 50 copies/mL or more (week 48) | 0.4% vs 1.1%vs DTG + F/TAFNCT03110380 | —Trial running · NCT06133686 |
| CD4 count, change (week 48) | 278 vs 289vs DTG + F/TAFNCT026079566 other results
| —Trial running · NCT06133686 |
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir
- 92.4% vs 93%vs ABC/DTG/3TCNCT02607930
5 other results
- 81.5% vs 84.1% NCT02607930
- 87.9% vs 89.8% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 96.9% vs 93.9% NCT02397694
- 96.9% vs 90.9% NCT02397694
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
CD4 count, change (week 48)
- Bictegravir
- 278 vs 289vs DTG + F/TAFNCT02607956
6 other results
- 299 vs 317 NCT02607930
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 180 vs 201 NCT02607956
- 235 vs 228 NCT02607930
- 18 vs 36 NCT03110380
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bictegravir: 4 of 4 rows · Cabotegravir (Apretude): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bictegravir |
|---|---|
| Dropout rate | 18.7%a NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results17.1%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 11.9% NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 20%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 1.2%a NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results0%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination — NCT04530630 · Phase 4 · registry result, not featured evidence — NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination —50 mg NCT02275065 · Phase 1 · registry result, not featured evidence —100 mg NCT02275065 · Phase 1 · registry result, not featured evidence —25 mg NCT02275065 · Phase 1 · registry result, not featured evidence —5 mg NCT02275065 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 20%a NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results14%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 4% NCT05405751 · Phase 4 · registry result, not featured evidence 0% NCT03656783 · Phase 3 · registry result, not featured evidence —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 12 more resultsdiarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · HIV · phase 3 loose stool/ diarrhea 25% NCT04530630 · Phase 4 · registry result, not featured evidence shortness of breath 8% NCT03656783 · Phase 3 · registry result, not featured evidence diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination 50 mg fatigue 25% (placebo 0%) papule 25% (placebo 0%) arthropod bite 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 100 mg arthropod bite 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence 25 mg headache 25% (placebo 25%) arthropod bite 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 5 mg blood creatine phosphokinase increased 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bictegravir
show 2 more results
show 5 more results
show 12 more results
show 6 more results
show 10 more results
show 2 more results
show 2 more results
show 4 more results
show 4 more results
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Cabotegravir (Apretude)'s landscape